The CoF slopes for dapagliflozin were significantly lower
than for glipizide, irrespective of which glycaemic variable
(HbA1c or FPG) or analysis set was used (Figure 1C and D;
Table S1). Using the full analysis set, the CoF for HbA1c from 18
to 104 weeks showed a rise of 0.13%/year [(1.4 mmol/mol/year)
95% CI 0.06 (0.7), 0.20 (2.2)] with dapagliflozin and a rise
of 0.59%/year [(6.4 mmol/mol/year) 95% CI 0.48 (5.2), 0.71
(7.8)] with glipizide, resulting in a dapagliflozin versus glipizide
difference of −0.46%/year [(−5.0 mmol/mol/year) 95%
CI −0.60 (−6.6), −0.33 (−3.6); p=0.0001). Corresponding
values for FPG were 0.28 mmol/l/year (95% CI 0.10, 0.46),
0.77 mmol/l/year (95% CI 0.50, 1.04) and −0.48 mmol/l/year
(95% CI −0.81, −0.16; p=0.0033), respectively. Using the completers
analysis set, CoF slopes for HbA1c and FPG were
The CoF slopes for dapagliflozin were significantly lowerthan for glipizide, irrespective of which glycaemic variable(HbA1c or FPG) or analysis set was used (Figure 1C and D;Table S1). Using the full analysis set, the CoF for HbA1c from 18to 104 weeks showed a rise of 0.13%/year [(1.4 mmol/mol/year)95% CI 0.06 (0.7), 0.20 (2.2)] with dapagliflozin and a riseof 0.59%/year [(6.4 mmol/mol/year) 95% CI 0.48 (5.2), 0.71(7.8)] with glipizide, resulting in a dapagliflozin versus glipizidedifference of −0.46%/year [(−5.0 mmol/mol/year) 95%CI −0.60 (−6.6), −0.33 (−3.6); p=0.0001). Correspondingvalues for FPG were 0.28 mmol/l/year (95% CI 0.10, 0.46),0.77 mmol/l/year (95% CI 0.50, 1.04) and −0.48 mmol/l/year(95% CI −0.81, −0.16; p=0.0033), respectively. Using the completersanalysis set, CoF slopes for HbA1c and FPG were
การแปล กรุณารอสักครู่..
